Prediction of Chronic Pain by the Pain Monitor (D3C)
The skin conductance algesimeter (Pain Monitor™, Med-Storm Innovation AS, NO-0264 Oslo, Norway)) reflects the sympathetic nervous system by the measurement of the skin conductance of the palm of the hand. SCA detects nociceptive pain fast and continuously, specific to the individual, with higher sensitivity and specificity than other available objective methods.
The skin conductance response to a calibrated noxious stimulus varies among patients. It defines two types of people depending on its magnitude.
The investigators assume that the importance of skin conductance response to a noxious stimulus predicts the occurrence of chronic pain in patients operated by thoracotomy.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Prediction of the Occurrence of Chronic Pain After Thoracotomy by Measuring Preoperative Skin Conductance (Pain Monitor Device)|
- Prediction of chronic pain [ Time Frame: one year after surgery ]Prediction of chronic pain by the measurement of skin conductance
- Prediction of the postoperative pain [ Time Frame: 5 days postoperatively ]Prediction of the postoperative pain by the measurement of skin conductance. Postoperative pain is assessed (pain score) at least twice each day at rest and during mobilisation.
- Prediction of the postoperative antalgic requirement [ Time Frame: 5 days postoperatively ]Prediction of the postoperative analgesic requirement by the measurement of skin conductance. The analgesic requirement is evaluated by the amount of epidural analgesics.
- Prediction of the postoperative antalgic requirement by the genetic study [ Time Frame: One year after surgery ]Prediction of the postoperative antalgic requirement by the genetic study
- Effect of remifentanil on skin conductance [ Time Frame: One hour after anesthesia ]Skin conductance is measured before and after a calibrated noxious stimulus. This test is performed after the induction of anesthesia (propofol) and a first time before remifentanil administration and a second time after.
Biospecimen Retention: Samples With DNA
|Study Start Date:||April 2012|
|Estimated Study Completion Date:||September 2018|
|Estimated Primary Completion Date:||September 2018 (Final data collection date for primary outcome measure)|
Device: Pain Monitor
Measurement of cutaneous conductance
Please refer to this study by its ClinicalTrials.gov identifier: NCT01595711
|Contact: Marc Fischler, MD||4652442 ext firstname.lastname@example.org|
|Suresnes, Ile de France, France, 92151|
|Contact: Morgan Le Guen, MD 46252442 ext 00331 email@example.com|
|Strasbourg, France, 67091|
|Contact: Jean Hentz, MD 69551271 ext 003 firstname.lastname@example.org|
|Principal Investigator: Jean Hentz, MD|
|Principal Investigator:||Morgan Le Guen, MD||Hopital Foch|